[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"endovascular-aortic-repair\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:endovascular-aortic-repair":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,52,93,117,138],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":32,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":4},"100629878","real-world-data-collection-of-gore-devices-used-in-the-endovascular-treatment-of-aortic-aneurysms-which-incorporate-visceral-arteries-100629878",false,"NCT07480395","Real-World Data Collection of GORE Devices Used In the Endovascular Treatment of Aortic Aneurysms Which Incorporate Visceral Arteries.","The ENVISION Registry: REal-World Data CollectioN of GORE deVIceS Used In the endOvascular treatmeNt of Aortic Aneurysms Which Incorporate Visceral Arteries.","ENVISION","Inclusion Criteria:\n\n1. Informed Consent Form (ICF) is signed by Subject.\n2. Age ≥ 18 years at time of informed consent signature.\n3. Patient presents with thoracoabdominal, pararenal, juxtarenal, or short-neck infrarenal aortic pathology suitable for endovascular repair.\n4. Patient requires the incorporation of ≥ 1 visceral artery and is suitable for use of at least 1 GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis (BXB) as a bridging stent (Note: Up to six (6) visceral arteries may be incorporated).\n5. Patient is willing to adhere to the institutional standard of care follow-up.\n\nExclusion Criteria:\n\n1. Patient has a prior visceral artery stenting not associated with registry procedure.\n2. Patient treated for acute or sub-acute dissection, \\\u003C90 days from onset of symptoms\n3. Patient is intended to be treated with a parallel grafting (e.g., chimney, periscope, sandwich) or octopus technique.\n4. Known hypersensitivity to heparin or a previous incident of Heparin-Induced Thrombocytopenia (HIT) type II.\n5. Patient has known coagulation disorders including hypercoagulability that are not amenable to treatment.\n6. Patient has a life expectancy \\\u003C 1-year.\n7. Patient is participating in an investigational study which may confound registry results, unless approved by Gore","ALL","18 Years",{"count":20,"type":21},400,"ESTIMATED","5 Years","OBSERVATIONAL","The registry population consists of patients presenting with complex aortic pathologies amenable to endovascular aortic repair that requires the incorporation of bridging stents to maintain visceral artery perfusion",[26,27,28,29,30,31],"Complex Aortic Aneurysms","Thoracoabdominal Aneurysm","Fenestrated Endovascular Aortic Repair","Endovascular Aortic Repair","Abdominal Aorta Aneurism","Chronic Dissection",[33,34,35,36,37,38,39],"FEVAR","BEVAR","TAAA","AAA","Visceral","aortic aneurysm","PMEGs","NOT_YET_RECRUITING","2026-05-27",{"date":43,"type":44},"2026-06-01","ACTUAL",{"date":46,"type":21},"2026-12",{"date":48,"type":21},"2035-12",{"name":50,"class":51},"W.L.Gore & Associates","INDUSTRY",{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":60,"sex":17,"minAge":61,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":72,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":92},"100633550","exoskeleton-vs-standard-lead-apron-in-evar-procedures-100633550","NCT07528144","Exoskeleton vs. Standard Lead Apron in EVAR Procedures","Radiation Exposure and Operator Musculoskeletal Strain in Endovascular Aortic Repair: a Randomized Trial of Exoskeleton vs. Standard Aprons","PROTECT-EVAR","Inclusion Criteria:\n\n* age 35 years or older\n* written informed consent obtained\n* vascular surgeon with substantial experience in endovascular procedures\n* active participation in endovascular aortic repair procedures as a primary operator or assistant\n* high procedural volume in endovascular interventions\n\nExclusion Criteria:\n\n* refusal or inability to provide informed consent\n* medical contraindications to the use of standard lead aprons or the exoskeleton-supported radiation protection system\n* health conditions preventing safe participation in study procedures",true,"35 Years",{"count":63,"type":21},2,"INTERVENTIONAL",[66],"NA","The goal of this clinical trial is to learn whether an exoskeleton-supported radiation protection system can reduce radiation exposure and musculoskeletal strain in vascular surgeons during endovascular aortic repair procedures, compared with standard lead aprons. Researchers will compare procedures performed with exoskeleton-supported protection and procedures performed with standard lead aprons. Radiation exposure, physical strain, fatigue, and discomfort will be assessed during and after procedures.",[69,29,70,71],"Radiation Exposure to Operator","Musculoskeletal Strain","Occupational Radiation Exposure",[73,34,74,75,76,77,78,79,80],"EVAR","IBD-EVAR","Exoskeleton","Lead Apron","Occupational Safety","Ionizing Radiation","Vascular Surgeon","Ergonomics","RECRUITING","2026-04-07",{"date":84,"type":44},"2026-04-14",{"date":86,"type":44},"2025-11-03",{"date":88,"type":21},"2027-06-17",{"name":90,"class":91},"Samodzielny Publiczny Szpital Kliniczny nr 2 PUM","OTHER",1,{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":99,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":64,"phases":103,"briefSummary":104,"conditions":105,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":4},"100591037","pre-emptive-coil-embolization-in-endovascular-aortic-repair-100591037","NCT06975215","Pre-emptive Coil Embolization in Endovascular Aortic Repair","Pre-emptive Coil Embolization in Endovascular Aortic Repair: The PRIZE Study","PRIZE","Inclusion Criteria:\n\n* Abdominal aortic aneurysms with a maximum aortic diameter above the threshold for repair level.\n* High-risk criteria for type 2 endoleaks\n\nExclusion Criteria:\n\n* Does not fulfill instructions for use for standard EVAR\n* Contraindication for EVAR\n* Life expectancy less than 2 years",{"count":102,"type":21},332,[66],"Abdominal aortic aneurysms are often treated with a minimally invasive procedure called endovascular aortic repair (EVAR). While EVAR is widely used, it can sometimes lead to complications over time, and some patients may require further procedures. One of the main issues is endoleak, which occurs when blood continues to flow into the aneurysm sac after treatment. This often happens because small nearby blood vessels, or other sources, continue to supply blood to the aneurysm.\n\nA potentialy strategy to reduce the risk of endoleak is pre-emptive embolization-a technique used during EVAR to block these sources of persistent blood flow. This can include embolization of side branches, the aneurysm sac, or other contributing vessels. Early findings suggest that pre-emptive embolization may lower the risk of endoleaks, but it is still uncertain whether it improves long-term outcomes.\n\nThe PRIZE study (Randomized Controlled Trial on Pre-emptive Coil Embolization in Endovascular Aortic Repair) is designed to answer this question. In this research, patients are randomly assigned to one of two groups: one group will receive EVAR with pre-emptive embolization, and the other will receive EVAR without it.\n\nTwo main outcomes will be assessed. The first is aneurysm sac regression at two years, meaning a reduction in the size of the aneurysm sac after treatment. This is important because sac shrinkage after EVAR has been linked to lower overall mortality, even though the exact reasons for this are not yet fully understood. The second main outcome is the rate of aortic-related events over five years, as ensuring the long-term durability of treatment is a key goal of this study. Secondary outcomes, including quality of life, patient satisfaction, and cost-effectiveness will also be evaluated.\n\nCurrently, there is no clear agreement on whether pre-emptive embolization should be routinely used during EVAR. In a recent international survey, 76% of aortic specialists agreed that more evidence is needed. The PRIZE study aims to provide that evidence. If pre-emptive embolization proves effective, it could become a standard addition to EVAR, helping to improve both the immediate success and long-term durability of treatment. If not, the study will help avoid unnecessary procedures, ensuring patients receive only treatments that offer real benefits.",[106,29,107],"Abdominal Aneurysm","Endoleak","2025-05-07",{"date":110,"type":44},"2025-05-16",{"date":112,"type":21},"2025-09-01",{"date":114,"type":21},"2033-09-01",{"name":116,"class":91},"Uppsala University",{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":124,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":126,"conditions":127,"keywords":4,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":134,"leadSponsor":136,"locationsCount":92},"100544858","semibranch-registry---retrospective-100544858","NCT06374355","Semibranch Registry - Retrospective","Outcome of the Semibranch in Pararenal and Thoracoabdominal Aortic Pathologies. A Retrospective, Multicentre Registry","* Patient has been treated with the semibranch stentgraft\n* Patient is over 18 years old",{"count":125,"type":21},100,"The goal of this registry is to evaluate the semibranch in branched endovascular arotic repair, which is a new tool in endovascular branched aortic repair.",[128,29,129],"Aortic Aneurysm","Stent-Graft Endoleak","2024-07-02",{"date":132,"type":44},"2024-07-03",{"date":130,"type":44},{"date":135,"type":21},"2030-10",{"name":137,"class":91},"University Hospital Muenster",{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":144,"targetDuration":145,"studyType":23,"phases":4,"briefSummary":146,"conditions":147,"keywords":4,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":92},"100520629","outcome-of-the-semibranch-in-pararenal-and-thoracoabdominal-aortic-pathologies-a-prospective-multicentre-registry-100520629","NCT06059053","Outcome of the Semibranch in Pararenal and Thoracoabdominal Aortic Pathologies. A Prospective, Multicentre Registry.","Inclusion Criteria:\n\n* 18 years or older\n* Presence of pararenal or thoracoabdominal aortic pathology\n* Treatment planned a semibranch device branch from Artivion\n* Availability of the patients during the follow up period\n* Informing patients about the study and providing written informed consent\n\nExclusion Criteria:\n\n* Women of childbearing age\n* Patients under 18 years",{"count":125,"type":21},"1 Year","The goal of this registry is to evaluate the semibranch in branched endovascular aortic repair, which is a new tool in endovascular branched aortic repair.",[128,29,129],"2024-03-25",{"date":150,"type":44},"2024-03-26",{"date":152,"type":44},"2024-01-12",{"date":154,"type":21},"2027-03-31",{"name":137,"class":91}]